RT Journal Article
SR Electronic
T1 Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2981
OP 2990
DO 10.21873/invivo.12593
VO 35
IS 5
A1 JINDRICH KOPECKY
A1 ONDREJ KUBECEK
A1 TOMAS BUCHLER
A1 BOHUSLAV MELICHAR
A1 ALEXANDR POPRACH
A1 MILADA ZEMANOVA
A1 JANA KATOLICKA
A1 IGOR KISS
A1 JAROSLAV HAJEK
A1 HANA STUDENTOVA
A1 MARTINA SPISAROVA
YR 2021
UL http://iv.iiarjournals.org/content/35/5/2981.abstract
AB Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pre-treated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.